Why Graphite Bio (GRPH) Shares Are Plunging Today – Graphite Bio (NASDAQ:GRPH)
[ad_1] Graphite Bio Inc GRPH voluntarily paused the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) following a serious adverse event in the first patient dosed with…